Corcept Therapeutics, Inc. (CORT)
116.23
+2.20
(+1.93%)
USD |
NASDAQ |
Oct 02, 16:00
116.23
0.00 (0.00%)
After-Hours: 20:00
Corcept Therapeutics Enterprise Value : 12.24B for Oct. 2, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 02, 2026 | 12.24B |
| October 01, 2026 | 12.01B |
| September 30, 2026 | 12.14B |
| September 29, 2026 | 12.08B |
| September 28, 2026 | 12.18B |
| September 25, 2026 | 12.23B |
| September 24, 2026 | 12.49B |
| September 23, 2026 | 11.89B |
| September 22, 2026 | 12.38B |
| September 21, 2026 | 11.98B |
| September 18, 2026 | 11.60B |
| September 17, 2026 | 12.10B |
| September 16, 2026 | 11.77B |
| September 15, 2026 | 11.66B |
| September 14, 2026 | 11.77B |
| September 11, 2026 | 11.87B |
| September 10, 2026 | 12.10B |
| September 09, 2026 | 12.19B |
| September 08, 2026 | 12.00B |
| September 04, 2026 | 11.75B |
| September 03, 2026 | 11.87B |
| September 02, 2026 | 11.62B |
| September 01, 2026 | 11.94B |
| August 31, 2026 | 11.93B |
| August 28, 2026 | 11.99B |
| Date | Value |
|---|---|
| August 27, 2026 | 12.32B |
| August 26, 2026 | 12.63B |
| August 25, 2026 | 13.04B |
| August 24, 2026 | 13.00B |
| August 21, 2026 | 12.89B |
| August 20, 2026 | 12.77B |
| August 19, 2026 | 12.55B |
| August 18, 2026 | 12.45B |
| August 17, 2026 | 12.35B |
| August 14, 2026 | 12.05B |
| August 13, 2026 | 11.63B |
| August 12, 2026 | 11.81B |
| August 11, 2026 | 11.77B |
| August 10, 2026 | 12.03B |
| August 07, 2026 | 11.66B |
| August 06, 2026 | 11.35B |
| August 05, 2026 | 11.65B |
| August 04, 2026 | 11.55B |
| August 03, 2026 | 11.87B |
| July 31, 2026 | 12.06B |
| July 30, 2026 | 12.47B |
| July 29, 2026 | 9.732B |
| July 28, 2026 | 9.866B |
| July 27, 2026 | 9.535B |
| July 24, 2026 | 9.993B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Eli Lilly & Co. | 1.122T |
| Pfizer Inc. | 210.23B |
| Aclaris Therapeutics, Inc. | 524.12M |
| Bristol Myers Squibb Co. | 158.92B |
| Liquidia Corp. | 2.451B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 42.14M |
| Revenue (Quarterly) | 256.15M |
| Total Expenses (Quarterly) | 214.01M |
| EPS Diluted (Quarterly) | 0.356 |
| Gross Profit Margin (Quarterly) | 98.41% |
| Profit Margin (Quarterly) | 16.45% |
| Earnings Yield | 0.36% |
| Operating Earnings Yield | 0.05% |
| Normalized Earnings Yield | 0.3602 |